Anaphylaxis - Pipeline Review, H2 2020
Anaphylaxis - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaphylaxis - Pipeline Review, H2 2020, provides an overview of the Anaphylaxis (Immunology) pipeline landscape.
Anaphylaxis is a severe, potentially life-threatening allergic reaction. Anaphylaxis symptoms include dizziness, nausea, vomiting or diarrhea, feeling of warmth, constriction of the airways and a swollen tongue or throat. Risk factors include personal history of anaphylaxis, allergies or asthma and family history. Treatment includes beta-agonist, antihistamines and cortisone.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anaphylaxis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Anaphylaxis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Anaphylaxis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Anaphylaxis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 4, 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Anaphylaxis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaphylaxis - Pipeline Review, H2 2020, provides an overview of the Anaphylaxis (Immunology) pipeline landscape.
Anaphylaxis is a severe, potentially life-threatening allergic reaction. Anaphylaxis symptoms include dizziness, nausea, vomiting or diarrhea, feeling of warmth, constriction of the airways and a swollen tongue or throat. Risk factors include personal history of anaphylaxis, allergies or asthma and family history. Treatment includes beta-agonist, antihistamines and cortisone.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anaphylaxis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Anaphylaxis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Anaphylaxis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Anaphylaxis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 4, 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Anaphylaxis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Anaphylaxis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Anaphylaxis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anaphylaxis (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anaphylaxis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anaphylaxis (Immunology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anaphylaxis (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anaphylaxis (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Anaphylaxis - Overview
Anaphylaxis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Anaphylaxis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Anaphylaxis - Companies Involved in Therapeutics Development
Aquestive Therapeutics Inc
ARS Pharmaceuticals Inc
Bryn Pharma LLC
G2B Pharma Inc
Great Bay Bio Holdings Ltd
Insys Therapeutics Inc
JDP Therapeutics Inc
MannKind Corp
Merck & Co Inc
Pharmacin BV
Shenox Pharmaceuticals LLC
Anaphylaxis - Drug Profiles
epinephrine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epinephrine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epinephrine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epinephrine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epinephrine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epinephrine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GBB-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HLK-0006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JDP-207 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize FcgR1 for Autoimmune Arthritis, Pulmonary Inflammation, Systemic Anaphylaxis and Thrombocytopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize FcgRIIa for Autoimmune Arthritis, Pulmonary Inflammation, Systemic Anaphylaxis and Thrombocytopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHX-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XL-499 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Anaphylaxis - Dormant Projects
Anaphylaxis - Product Development Milestones
Featured News & Press Releases
Oct 29, 2020: Insignis Therapeutics and HLK Pharmacin receive FDA IND clearance to initiate a phase 1 trial with IN-001 for oral anaphylaxis treatment
Aug 20, 2020: Aquestive Therapeutics initiates Phase 1 Pharmacokinetic trial of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) in development for treatment of allergic reactions including anaphylaxis
Aug 10, 2020: Aquestive Therapeutics receives FDA Fast Track Designation for AQST-108 (sublingual film formulation delivering systemic epinephrine) for treatment of allergic reactions including anaphylaxis
Jul 13, 2020: ARS Pharmaceuticals announces new patent on ARS-1 (epinephrine nasal spray)
Jun 29, 2020: Aquestive Therapeutics files IND for pharmacokinetic clinical trials of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for anaphylaxis treatment
Jun 10, 2020: Bryn Pharma announces the Publication of positive results from its Intranasal Epinephrine Preclinical Study program In three Peer-Reviewed Scientific Journals
May 04, 2020: Neurelis announces that Intravail Licensee, ARS Pharmaceuticals intranasal epinephrine product, demonstrates bioequivalent exposure to epinephrine injectors
Apr 06, 2020: Bryn Pharma presents data demonstrating comparable pharmacokinetic and pharmacodynamic effects of intranasal Epinephrine to intramuscular Epinephrine in adults
Mar 02, 2020: ARS Pharmaceuticals to present new data from Neffy (ARS-1) studies at AAAAI 2020 annual meeting
Feb 06, 2020: Aquestive Therapeutics announces FDA confirmed 505(b)(2) pathway for AQST-108 (sublingual film formulation delivering systemic epinephrine) for anaphylaxis treatment
Nov 10, 2019: Bryn Pharma Research on Epinephrine Nasal Spray Presented at The American College of Allergy, Asthma and Immunology Annual Meeting
Oct 29, 2019: Bryn Pharma presents data demonstrating patient preference for bi-dose epinephrine nasal spray over EpiPen
Oct 10, 2019: Bryn Pharma completes dosing in pivotal clinical trial designed to support U.S. approval of Intranasal Epinephrine Spray
Sep 30, 2019: Aquestive Therapeutics Announces Successful Completion of Phase 1 Trial for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine)
Jun 04, 2019: ARS Pharmaceuticals announces results from EPI-04 clinical study of ARS-1 Intranasal Epinephrine Spray in Allergy Patients with Allergic Rhinitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Anaphylaxis - Overview
Anaphylaxis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Anaphylaxis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Anaphylaxis - Companies Involved in Therapeutics Development
Aquestive Therapeutics Inc
ARS Pharmaceuticals Inc
Bryn Pharma LLC
G2B Pharma Inc
Great Bay Bio Holdings Ltd
Insys Therapeutics Inc
JDP Therapeutics Inc
MannKind Corp
Merck & Co Inc
Pharmacin BV
Shenox Pharmaceuticals LLC
Anaphylaxis - Drug Profiles
epinephrine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epinephrine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epinephrine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epinephrine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epinephrine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epinephrine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GBB-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HLK-0006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JDP-207 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize FcgR1 for Autoimmune Arthritis, Pulmonary Inflammation, Systemic Anaphylaxis and Thrombocytopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize FcgRIIa for Autoimmune Arthritis, Pulmonary Inflammation, Systemic Anaphylaxis and Thrombocytopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHX-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XL-499 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Anaphylaxis - Dormant Projects
Anaphylaxis - Product Development Milestones
Featured News & Press Releases
Oct 29, 2020: Insignis Therapeutics and HLK Pharmacin receive FDA IND clearance to initiate a phase 1 trial with IN-001 for oral anaphylaxis treatment
Aug 20, 2020: Aquestive Therapeutics initiates Phase 1 Pharmacokinetic trial of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) in development for treatment of allergic reactions including anaphylaxis
Aug 10, 2020: Aquestive Therapeutics receives FDA Fast Track Designation for AQST-108 (sublingual film formulation delivering systemic epinephrine) for treatment of allergic reactions including anaphylaxis
Jul 13, 2020: ARS Pharmaceuticals announces new patent on ARS-1 (epinephrine nasal spray)
Jun 29, 2020: Aquestive Therapeutics files IND for pharmacokinetic clinical trials of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for anaphylaxis treatment
Jun 10, 2020: Bryn Pharma announces the Publication of positive results from its Intranasal Epinephrine Preclinical Study program In three Peer-Reviewed Scientific Journals
May 04, 2020: Neurelis announces that Intravail Licensee, ARS Pharmaceuticals intranasal epinephrine product, demonstrates bioequivalent exposure to epinephrine injectors
Apr 06, 2020: Bryn Pharma presents data demonstrating comparable pharmacokinetic and pharmacodynamic effects of intranasal Epinephrine to intramuscular Epinephrine in adults
Mar 02, 2020: ARS Pharmaceuticals to present new data from Neffy (ARS-1) studies at AAAAI 2020 annual meeting
Feb 06, 2020: Aquestive Therapeutics announces FDA confirmed 505(b)(2) pathway for AQST-108 (sublingual film formulation delivering systemic epinephrine) for anaphylaxis treatment
Nov 10, 2019: Bryn Pharma Research on Epinephrine Nasal Spray Presented at The American College of Allergy, Asthma and Immunology Annual Meeting
Oct 29, 2019: Bryn Pharma presents data demonstrating patient preference for bi-dose epinephrine nasal spray over EpiPen
Oct 10, 2019: Bryn Pharma completes dosing in pivotal clinical trial designed to support U.S. approval of Intranasal Epinephrine Spray
Sep 30, 2019: Aquestive Therapeutics Announces Successful Completion of Phase 1 Trial for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine)
Jun 04, 2019: ARS Pharmaceuticals announces results from EPI-04 clinical study of ARS-1 Intranasal Epinephrine Spray in Allergy Patients with Allergic Rhinitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Anaphylaxis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Anaphylaxis - Pipeline by Aquestive Therapeutics Inc, H2 2020
Anaphylaxis - Pipeline by ARS Pharmaceuticals Inc, H2 2020
Anaphylaxis - Pipeline by Bryn Pharma LLC, H2 2020
Anaphylaxis - Pipeline by G2B Pharma Inc, H2 2020
Anaphylaxis - Pipeline by Great Bay Bio Holdings Ltd, H2 2020
Anaphylaxis - Pipeline by Insys Therapeutics Inc, H2 2020
Anaphylaxis - Pipeline by JDP Therapeutics Inc, H2 2020
Anaphylaxis - Pipeline by MannKind Corp, H2 2020
Anaphylaxis - Pipeline by Merck & Co Inc, H2 2020
Anaphylaxis - Pipeline by Pharmacin BV, H2 2020
Anaphylaxis - Pipeline by Shenox Pharmaceuticals LLC, H2 2020
Anaphylaxis - Dormant Projects, H2 2020
Number of Products under Development for Anaphylaxis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Anaphylaxis - Pipeline by Aquestive Therapeutics Inc, H2 2020
Anaphylaxis - Pipeline by ARS Pharmaceuticals Inc, H2 2020
Anaphylaxis - Pipeline by Bryn Pharma LLC, H2 2020
Anaphylaxis - Pipeline by G2B Pharma Inc, H2 2020
Anaphylaxis - Pipeline by Great Bay Bio Holdings Ltd, H2 2020
Anaphylaxis - Pipeline by Insys Therapeutics Inc, H2 2020
Anaphylaxis - Pipeline by JDP Therapeutics Inc, H2 2020
Anaphylaxis - Pipeline by MannKind Corp, H2 2020
Anaphylaxis - Pipeline by Merck & Co Inc, H2 2020
Anaphylaxis - Pipeline by Pharmacin BV, H2 2020
Anaphylaxis - Pipeline by Shenox Pharmaceuticals LLC, H2 2020
Anaphylaxis - Dormant Projects, H2 2020
LIST OF FIGURES
Number of Products under Development for Anaphylaxis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
Number of Products under Development for Anaphylaxis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
